ArticleResearch and practice in thrombosis and haemostasis2026
Venous thromboembolic and bleeding risk in population with obesity hospitalized for an acute medical illness receiving enoxaparin for thromboprophylaxis.
Article in Research and practice in thrombosis and haemostasis, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Patients with obesity hospitalized for acute medical illness are at increased venous thromboembolism (VTE) risk, but evidence on predictors of VTE and major bleeding (MB) to optimize individual risk stratification and thromboprophylaxis remains limited, in particular for patients with extreme obesity. Objectives: This study assessed pharmacologic regimen, event rates, and predictors for VTE and MB among hospitalized medical patients with obesity receiving thromboprophylaxis using enoxaparin. Methods: Patients with body mass index (BMI) of ≥30 kg/m Results: Among 58,186 eligible patients, 17,398 (30%) had a BMI of >40 kg/m Conclusion: Acutely ill patients with obesity received enoxaparin for shorter duration than their hospitalization, with over half receiving a high-dose adjustment by weight. The VTE rates were nonnegligible in this population and exceed MB rates across illness subgroups, suggesting a need for individualized risk stratification to optimize thromboprophylaxis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.